These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 29215041)

  • 1. CRISPR/Cas9 delivery with one single adenoviral vector devoid of all viral genes.
    Ehrke-Schulz E; Schiwon M; Leitner T; Dávid S; Bergmann T; Liu J; Ehrhardt A
    Sci Rep; 2017 Dec; 7(1):17113. PubMed ID: 29215041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene Therapy with CRISPR/Cas9 Coming to Age for HIV Cure.
    Soriano V
    AIDS Rev; 2017; 19(3):167-172. PubMed ID: 29019352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.
    Maggio I; Liu J; Janssen JM; Chen X; Gonçalves MA
    Sci Rep; 2016 Nov; 6():37051. PubMed ID: 27845387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of HIV-1 infection of primary CD4+ T-cells by gene editing of CCR5 using adenovirus-delivered CRISPR/Cas9.
    Li C; Guan X; Du T; Jin W; Wu B; Liu Y; Wang P; Hu B; Griffin GE; Shattock RJ; Hu Q
    J Gen Virol; 2015 Aug; 96(8):2381-2393. PubMed ID: 25854553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different Methods of Delivering CRISPR/Cas9 Into Cells.
    Chandrasekaran AP; Song M; Kim KS; Ramakrishna S
    Prog Mol Biol Transl Sci; 2018; 159():157-176. PubMed ID: 30340786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of viral vectors as vehicles for DMD gene editing.
    Maggio I; Chen X; Gonçalves MA
    Genome Med; 2016 May; 8(1):59. PubMed ID: 27215286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a CRISPR/Cas9 genome editing toolbox for Corynebacterium glutamicum.
    Liu J; Wang Y; Lu Y; Zheng P; Sun J; Ma Y
    Microb Cell Fact; 2017 Nov; 16(1):205. PubMed ID: 29145843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo Delivery of CRISPR/Cas9 for Therapeutic Gene Editing: Progress and Challenges.
    Mout R; Ray M; Lee YW; Scaletti F; Rotello VM
    Bioconjug Chem; 2017 Apr; 28(4):880-884. PubMed ID: 28263568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methods for In Vivo CRISPR/Cas Editing of the Adult Murine Retina.
    Hung SS; Li F; Wang JH; King AE; Bui BV; Liu GS; Hewitt AW
    Methods Mol Biol; 2018; 1715():113-133. PubMed ID: 29188510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adeno-Associated Virus-Mediated Delivery of CRISPR for Cardiac Gene Editing in Mice.
    Xu L; Gao Y; Lau YS; Han R
    J Vis Exp; 2018 Aug; (138):. PubMed ID: 30124643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral Delivery Systems for CRISPR.
    Xu CL; Ruan MZC; Mahajan VB; Tsang SH
    Viruses; 2019 Jan; 11(1):. PubMed ID: 30621179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro CRISPR-Cas9-mediated efficient Ad5 vector modification.
    Tang L; Gong M; Zhang P
    Biochem Biophys Res Commun; 2016 May; 474(2):395-399. PubMed ID: 27125457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A multifunctional non-viral vector for the delivery of MTH1-targeted CRISPR/Cas9 system for non-small cell lung cancer therapy.
    Wang Y; Tang Y; Zhao XM; Huang G; Gong JH; Yang SD; Li H; Wan WJ; Jia CH; Chen G; Zhang XN
    Acta Biomater; 2022 Nov; 153():481-493. PubMed ID: 36162766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas9-mediated correction of human genetic disease.
    Men K; Duan X; He Z; Yang Y; Yao S; Wei Y
    Sci China Life Sci; 2017 May; 60(5):447-457. PubMed ID: 28534256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
    Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
    FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Zhou ZP; Yang LL; Cao H; Chen ZR; Zhang Y; Wen XY; Hu J
    Hum Gene Ther; 2019 Sep; 30(9):1101-1116. PubMed ID: 31099266
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CRISPR/Cas9 Technology in Restoring Dystrophin Expression in iPSC-Derived Muscle Progenitors.
    Jin Y; Shen Y; Su X; Weintraub N; Tang Y
    J Vis Exp; 2019 Sep; (151):. PubMed ID: 31566614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.